Skip to main content
Displaying 1232 of 2959 articles.
The relatively simple and low-cost procedure could empower laboratories in low-resource areas to generate nanobodies against SARS-CoV-2, as well as other viruses.

The findings offer a new way to understand how some ants become total layabouts.

A trio of faulty genes fail to put the brakes on the immune system’s all-out assault on SARS-CoV-2, leading to the inflammatory overload characteristic of MIS-C.

Starving cancer cells of a key amino acid could potentially render tumors more vulnerable to the body’s natural immune response.

The body's first blush with a pathogen shapes how it will respond to vaccines. New evidence clarifies how this phenomenon works, mechanistically.

A diverse immune response hinges on naive B cells mingling with high affinity ones in the late-stage germinal center. Whether that helps or hinders, however, depends on the virus.

It's not just the number of mutations that matters. It's the failure to fix them too.

A novel method reduces the time required to identify novel antibiotic-producing DNA from weeks to days.

While most germinal centers shut down after a few weeks, some stay in business for more than six months. A new study helps explain why.

Breakthroughs in genetics, biochemistry, neuroscience, infectious disease, and drug development were a few of the year's highlights.